ERDERA has opened its Clinical Trial Call 2026 to support multinational early-phase clinical trials in rare diseases. The call will fund sponsor-led, GCP-compliant studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.
Preliminary results point interest across the rare disease research community, while highlighting underrepresentation of some countries and stakeholders
ERDERA interviews Dorica Dan, President of the Romanian Prader-Willi Association (RPWA), the Romanian National Alliance for Rare Diseases (RONARD) and the Romanian Rare Cancers Association, and Vice-President of EURORDIS–Rare Diseases Europe.
